Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Agnieszka Potęga"'
Autor:
Aleksandra Gajda-Walczak, Agnieszka Potęga, Agata Kowalczyk, Slawomir Sek, Sebastian Zięba, Artur Kowalik, Andrzej Kudelski, Anna M. Nowicka
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Despite significant progress in cancer therapy, cancer is still the second cause of mortality in the world. The necessity to make quick therapeutic decisions forces the development of procedures allowing to obtain a reliable result in a quic
Externí odkaz:
https://doaj.org/article/588bbe1a98164cbab79e5d6cff1964c6
Autor:
Agnieszka Potęga, Dominika Rafalska, Dawid Kazimierczyk, Michał Kosno, Aleksandra Pawłowicz, Witold Andrałojć, Ewa Paluszkiewicz, Tomasz Laskowski
Publikováno v:
Molecules, Vol 28, Iss 19, p 6812 (2023)
This work is the next step in studying the interplay between C-2028 (anticancer-active unsymmetrical bisacridine developed in our group) and the glutathione S-transferase/glutathione (GST/GSH) system. Here, we analyzed the concentration- and pH-depen
Externí odkaz:
https://doaj.org/article/495970c7078f4f1ebd453da375956528
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 11, Iss 6, Pp 791-798 (2021)
Unsymmetrical bisacridines (UAs) are a novel potent class of antitumor-active therapeutics. A significant route of phase II drug metabolism is conjugation with glutathione (GSH), which can be non-enzymatic and/or catalyzed by GSH-dependent enzymes. T
Externí odkaz:
https://doaj.org/article/af970ca62e2d4b51a1bbec8871eb1181
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 10, Iss 4, Pp 376-384 (2020)
5-Dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) is a promising antitumor compound developed in our laboratory. A better understanding of its metabolic transformations is still needed to explain the multidirectional mechanism of pharma
Externí odkaz:
https://doaj.org/article/48a49dfb8c9d4316a3e02459773ba5a2
Autor:
Joanna Pilch, Agnieszka Potęga, Agata Kowalczyk, Artur Kasprzak, Patrycja Kowalik, Piotr Bujak, Ewa Paluszkiewicz, Ewa Augustin, Anna M. Nowicka
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 201 (2023)
Selective therapy and controlled drug release at an intracellular level remain key challenges for effective cancer treatment. Here, we employed folic acid (FA) as a self-navigating molecule in nanoconjugates containing quantum dots (QDs) and β-cyclo
Externí odkaz:
https://doaj.org/article/157580cbc16649f0bec5421874deb28b
Autor:
Agnieszka Potęga
Publikováno v:
Molecules, Vol 27, Iss 16, p 5252 (2022)
The effectiveness of many anticancer drugs depends on the creation of specific metabolites that may alter their therapeutic or toxic properties. One significant route of biotransformation is a conjugation of electrophilic compounds with reduced gluta
Externí odkaz:
https://doaj.org/article/9687146d4f584e93acb4d3f411e20efb
Autor:
Michał Kosno, Tomasz Laskowski, Joanna E. Frackowiak, Agnieszka Potęga, Agnieszka Kurdyn, Witold Andrałojć, Julia Borzyszkowska-Bukowska, Katarzyna Szwarc-Karabyka, Zofia Mazerska
Publikováno v:
Molecules, Vol 27, Iss 13, p 3995 (2022)
Unsymmetrical bisacridines (UAs) represent a novel class of anticancer agents previously synthesized by our group. Our recent studies have demonstrated their high antitumor potential against multiple cancer cell lines and human tumor xenografts in nu
Externí odkaz:
https://doaj.org/article/a1af03541ea746f7ab40cf5703d38fc1
Autor:
Anna Mieszkowska, Anna M. Nowicka, Agata Kowalczyk, Agnieszka Potęga, Monika Pawłowska, Michał Kosno, Ewa Augustin, Zofia Mazerska
Publikováno v:
Pharmaceuticals, Vol 14, Iss 4, p 317 (2021)
New unsymmetrical bisacridines (UAs) demonstrated high activity not only against a set of tumor cell lines but also against human tumor xenografts in nude mice. Representative UA compounds, named C-2028, C-2045 and C-2053, were characterized in respe
Externí odkaz:
https://doaj.org/article/33875ddea39b432b90bf1e1d31950aa1
Publikováno v:
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis, Vol 11, Iss 6, Pp 791-798 (2021)
Journal of Pharmaceutical Analysis, Vol 11, Iss 6, Pp 791-798 (2021)
Unsymmetrical bisacridines (UAs) are a novel potent class of antitumor-active therapeutics. A significant route of phase II drug metabolism is conjugation with glutathione (GSH), which can be non-enzymatic and/or catalyzed by GSH-dependent enzymes. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5810d45c43801e4c4979898e457d99b9
http://europepmc.org/articles/PMC8740389
http://europepmc.org/articles/PMC8740389
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 10, Iss 4, Pp 376-384 (2020)
5-Dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) is a promising antitumor compound developed in our laboratory. A better understanding of its metabolic transformations is still needed to explain the multidirectional mechanism of pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cb55f852637b894190b72e9c6a9844a
https://doi.org/10.1016/j.jpha.2020.03.011
https://doi.org/10.1016/j.jpha.2020.03.011